BioSpectrum the business of Bio & Health Sciences ASIA EDITION

Roche, Voluntis reinvent cancer patient support

March 27, 2018 | News

ZEMY aims to improve care support for breast cancer patients.



Singapore - Today, Voluntis and Roche Pharma France announced that important milestones have been reached in the development of ZEMY, a digital therapeutic developed by Roche Pharma France in partnership with Voluntis since 2015. ZEMY aims to improve care support for breast cancer patients. Its co-construction with various stakeholders (patients, healthcare professionals, etc.) has been critical in developing its medical algorithms and validating its ease of use.

In addition, both partners have agreed to broaden their collaboration by extending ZEMY to all solid tumors, through Voluntis' Theraxium platform. Voluntis and Roche have therefore expanded their licensing and co-development agreement, in which Voluntis acts as the legal manufacturer of ZEMY, heading its technology and regulatory development, and Roche leads the clinical evaluation process and the future commercialization of the solution to oncology centers.

"At Roche, we always want to push ourselves to help patients more," said Christine Lhomel, Director of Medical Operations and Scientific Relations at Roche Pharma France. "We think that digital therapeutics like ZEMY can help breast cancer patients, and one day all cancer patients, better manage the symptoms related to their cancer treatment and thus make their daily lives a little easier."